---
layout: post
title: "Human Gene Therapy Products Incorporating Human Genome Editing; Guidance for Industry; Availability"
date: 2026-02-05 18:53:19 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-01788
original_published: 2024-01-30 00:00:00 +0000
significance: 8.00
---

# Human Gene Therapy Products Incorporating Human Genome Editing; Guidance for Industry; Availability

**Published:** February 05, 2026 18:53 UTC
**Source:** Federal Register
**Original Published:** January 30, 2024 00:00 UTC
**Document Number:** 2024-01788

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled "Human Gene Therapy Products Incorporating Human Genome Editing; Guidance for Industry." The guidance document provides recommendations to sponsors developing human gene therapy products incorporating genome editing (GE) of human somatic cells. Specifically, the guidance provides recommendations regarding information that should be provided in an investigational new drug (IND) application to assess the safety and quality of the investigational GE product, including information on product design, product manufacturing and testing, nonclinical safety assessment, and clinical trial design. The guidance announced in this notice finalizes the draft guidance of the same title dated March 2022.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/01/30/2024-01788/human-gene-therapy-products-incorporating-human-genome-editing-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2024-01788

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
